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Abstract
Throughout the last decade or so, Opioid related fatalities are at all-time high in the
United States. New Mexico’s problem with Opioids abuse in not a new phenomenon and a large
number of New Mexicans are losing their lives almost on a daily basis. The paper highlights the
alarming situation of overdose deaths caused specifically by the abuse of Prescription Opioids
and Heroin which, in 2016 alone have taken 347 lives in New Mexico. Policy makers along with
other stakeholders play a vital part in shaping the politics along with other interventions which
can help tackle the epidemic. The paper provides analysis of state policies along with other
initiatives taken to tackle the Opioids epidemic in New Mexico. After an in-depth analysis of the
situation in the state, the paper will conduct strengths, weaknesses, opportunities and threats
(SWOT) analysis of possible interventions and policies aimed at addressing rising overdose
deaths caused by Prescription Opioids and Heroin. Recommended interventions include,
Creation of Prescription Opioids and Heroin crisis Action Team, Implementation of Alternative
to Opiates program within the healthcare setting, Heroin Assisted Treatments as well as
considering Opioid Use Disorder as a qualifying condition for accessing Medical Cannabis.
Rising unnatural deaths caused by this epidemic is severe and all the stakeholders in New
Mexico must call for desperate measures to deal with such desperate times.
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Introduction
According to a report by President’s Commission on Combating Drug Addiction and
Opioid crisis, in 2016, 64,000 Americans lost their lives to drug abuse. Currently, the state of
New Mexico is ranked number 12th in the country in terms of overdose deaths linked to drug
abuse. The purpose of this paper is to understand the prescription Opioids and Heroin crisis in
New Mexico and what has led to aggravate this issue in the state.
Once the problem is highlighted, the paper will turn the attention to current strategies,
policies, interventions implemented in the state aiming at dealing with prescription opioids and
heroin crisis. Finally, by analyzing data and current practices, it will provide recommendations
concerning how existing practices can be modified as well as how evidence-based practices
implemented elsewhere, if implemented in New Mexico can help the cause in addressing the
issue of increasing overdose deaths caused by Prescribed opioids and Heroin.
In this paper, the overdose death data records are accessed through but not limited to New
Mexico indicator-based information system (NMIBIS) along with several other sources
including; Center for Disease Control and Prevention (CDC); New Mexico Department of Health
(NMDOH); and several other open sources including Drug Enforcement Agency (DEA);
National Institute of Health (NIH); Substance Abuse and Mental Health Services Administration
(SAMHSA); Center for Medicare and Medicaid services (CMS) and Office of the Medical
Investigator (OMI). The data provides all the information regarding overdose death rates, type of
opioid involved, as well as information including the demographics like age, gender, ethnicity
etc.
Analyzing the data will provide the resources to identify the problem at its root, and by
investigating the abuse of prescribed Opioids as well as illicit opioid Heroin, the severity of the
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issue leading to high levels of overdose deaths in the state will be revealed. By understanding the
issues and its implications on New Mexico and by conducting SWOT analysis of possible
policies and interventions, the paper will conclude by providing recommendations to curb the
ongoing prescription Opioid and Heroin crisis. This document will provide policy makers a
foundation of developing policies and formalizing interventions that are needed to address this
issue.
Literature Review
What are Opioids?
Opioids derived from opium are a class of drug that are used to treat pain. Opioid
medications work by binding to specific opioid receptors in the brain, spinal cord, and
gastrointestinal tract. Pain relievers which are legally available through doctor's prescription
(hydrocodone, oxycodone, morphine and many others), heroin (an illicit opioid) and fentanyl (a
form of synthetic opioid) are some of the examples. The way opioids work is simple, they
alleviate the pain signal to the brain which in turn leads to reduction in pain (National Institute of
Drug Abuse, n.d).
Categories of Opioids
Center for Disease Control and Prevention (CDC) Injury Center consider deaths and
nonfatal overdoses in four categories of opioids including:
1. Natural opioids (including codeine and morphine) and semi-synthetic opioids (medications like
hydrocodone, oxycodone)
2. Methadone (a synthetic opioid)
3. Synthetic opioids other than methadone (drugs like fentanyl)
4. Heroin, an illicit (illegally made) opioid produced from morphine.
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These categories are important to understand the type of Opioids involved in overdose
deaths. The paper will focus on the data using CDC injury center approach of classifying the opioid
involvement in causing overdose deaths in New Mexico over the period of last ten years.
Opioid Crisis
The severity of the drug abuse crisis in the United States is taking more than 175 deaths
every day with 64,000 deaths in 2016. Alarmingly, 43,000 out of these 64,000 deaths were
caused by Opioid Use Disorder (OUD). (Christie, Baker, Cooper, Kennedy, Madras & Bondi,
2017).
It is imperative to understand the underlying cause of Opioids abuse. When taken as
prescribed for a limited amount of time, Opioids are useful in relieving pain. However, the
problem arises when they are misused and taken in high quantity. Opioids tend to create a
euphoric feeling which then, gives birth to addictive behaviors. This addictive behavior is further
aggravated when a person on Opioid medication develops tolerance towards the drug and
experiences withdrawal symptoms such as body aches and nausea. People abuse Opioids not just
to get euphoric feelings but to get relief from such withdrawal symptoms. Dependence on
Opioids in particular is considered to be as a chronic, brain-based disorder with a high potential
for relapse (Timko, Schultz, Cucciare, Vittorio & Garrison, 2016). The current Opioid epidemic
in the United States is the outcome of the misuse and addiction of Opioids in all forms.
Awuah, Okyere, Curi and Pon and Stern (2016) blamed the crisis on increasing number
of prescriptions dispensed leading to increasing number of overdose deaths. Their research
highlighted the role of fewer safe pharmacologic options for managing pain and how this has led
to increasing use of opioids along with the increasing opioid related mortalities (p.24). The trend
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of increasing overdose deaths with increased prescribing of medications has been an ongoing
issue which must be dealt with in order to contain the crisis.
The Opioid crisis in the United States is causing high societal cost and negatively
affecting our communities. A study conducted in 2011 estimates the total societal costs of
prescription opioid abuse at $55.7 billion in 2007. The figure comprised of workplace costs
estimated at $25.6 billion (46%), $25.0 billion (45%) accounts for health care costs, along with
criminal justice costs mainly comprising of correctional facility and law enforcement which
accounted for $5.1 billion (9%) (Birnbaum, Cleveland, Roland, Schiller, Waldman, White, 2011,
p.657). The figure provides the picture for policy makers to understand the magnitude of the
adverse outcomes caused by the crisis and also highlight the need for addressing the issue which
is significantly burdening our economy.
As the focus of the paper will be on overdose deaths caused specifically due to the abuse
of Prescription opioids along with Heroin, the following section provides deeper understanding
on the abuse and misuse of these two categories and how the issue is resulting in an increasing
overdose death rate across the Nation as well as in New Mexico.
Prescribed Opioids. Prescribed opioids or prescription pain relivers are medications
recommended by physicians to the patients for treating pain usually more moderate to severe.
Opioids contains chemicals which help relax the body and alleviate pain which is why they are
used as medications (NIDA, n.d). Often, opioids are prescribed to treat severe pain and medical
conditions followed by surgery, accidents or condition like cancer. Prescribed opioid helps
patients to alleviate and manage their pain correctly if taken as prescribed. Despite being
obtained through prescription, increasing fatalities associated with opioid painkillers has led to
concerns about their misuse and abuse (Ferris, Lynskey, Morley & Winstock, 2017).
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America’s problem with prescription Opioids has been a growing concern for the past
several decades. “Prescription opioid medications has surged across the United States over the
last two decades which led to some inadvertent consequences causing fatal overdoses from these
drugs climbing from 4,000 in 1999 to more than 14,000 in 2014 (Stanhope, 2018). The amount
of opioid prescribed in the US peaked in 2010 and has been in decline since then. However, it is
also important to highlight here that the recent figures of the number of prescribed opioids are
three time higher than what it was in 1999. Prescribers wrote nearly a quarter of a billion opioid
prescriptions in 2013-2017 which is enough for every American adult to have their own bottle of
pills (CDC, n.d).
In order to find a cure for the Opioid crisis, it is important to acknowledge that the way
pain is treated must be changed, where only those who are in pain actually have access to
Opioids. Additionally, interventions to reduce non-medical uses leading to overdose deaths
should also be taken.
Prescription opioids use is associated with several serious health risks, and it is essential
to carefully consider the risks while using such medications. Dangers include Opioid use
disorder (addiction), overdoses, and eventually death. From 1999 to 2016, more than 200,000
people died in the United States from overdoses related to prescription opioids. Overdose deaths
involving prescription opioids were five times higher in 2016 compared to what they were in
1999 (CDC).
The figure below illustrates the national overdose deaths caused by prescription pain
relievers from 2002 to 2016. The figure leaves out the non-methadone synthesis due to deaths
caused by illicitly manufactured Fentanyl, to accurately reflect overdose deaths by prescribed
opioids.
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Figure 1: National Overdose deaths involving Opioid Pain Relievers
Retrieved from National Institute of Drug database (2018)

Heroin (Illicit Opioid). Heroin, an illegal, highly addictive drug processed from
morphine, is a naturally occurring substance extracted from the seed pod of certain varieties of
poppy plants (NIDA, n.d). Over-prescription of licit opioids over the period of last two decades
fueled the rapid surge in non-prescribed opioids - resulting in a large number of overdose deaths.
Furthermore, the availability of low-cost illegal Heroin and illicitly manufactured fentanyl made
the situation even worse and contributed in causing the current opioid epidemic.
Interestingly, there is also a significant amount of evidence which suggests that there is
causal relationship between abuse of prescribed opioids and use of Heroin. A study concluded
that almost 80% of persons who recently began using heroin had nonmedically used prescription
opioids before. (Balding, Compton & Jones, 2016).
The figure below provides a snapshot of the current number of overdose deaths caused
specifically by Heroin. The chart clearly depicts the increasing trends in terms of overdose
deaths caused by heroin in the US and highlights the need to address the issue, since the
overdose deaths increased more than seven-fold over the last fifteen years.
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Figure 2: Number of Overdose deaths caused by Heroin, US 2002-2017
Retrieved from National Institute of Drug database (2018)

Defining the Problem in New Mexico
The paper will now delve into understanding the growing prescription Opioids and
Heroin epidemic in New Mexico. To do this, it is imperative to review the history of prescription
Opioids and Heroin abuse in New Mexico and understand what caused the problem to aggravate
and how it has affected the local population.
Factors Contributing to the Current Epidemic
Over the last decade, New Mexico has been a victim of an increasing rate of overdose
deaths caused by prescription Opioid pain relievers and Heroin. This is not just the problem of
New Mexico but has been an ongoing crisis for the whole Nation. Prescription Opioids are
widely abused, and the role played by clinician’s prescribing practices, pharmaceutical
companies’ aggressive strategies, and other socio-economic factors leading to increase in
diversion and abuse is significant. This victimization can be attributed to several factors which
are mentioned below:
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Prescribing Opioids to chronic non-cancer patients. The patterns of rising overdose
deaths over the past 20 years can be attributed to the liberalization of laws governing the
prescribing of opioids for the treatment of chronic non-cancer pain by the state medical boards in
the late 1990s (Boswell, Grider, Helm, Janata, Manchikanti & Pampati, 2012). Over prescribing
of pain medications due to changing practices in the late 1990s clearly shows the increasing
trend of over dose deaths with increased prescribing in New Mexico. Physicians prescribing
higher opioid dosage and the consistent trend of prescribing to non-cancer patients over the past
few decades contributed significantly in fueling the crisis.
Aggressive marketing by pharmaceutical companies. The marketing strategies to
promote Opioid pain relievers since the late 1990s, when Opioids started being prescribed for
chronic conditions other than cancer, played a significant role in aiding the crisis of overdose
deaths. Regulations shifts largely driven by extremely weak evidence suggesting opioids are not
only highly effective, but also safe for chronic non-cancer pain have facilitated overuse of
Opioids. The scientific evidence for the effectiveness of opioids for chronic non-cancer pain
even after more than two decades remains unclear. (Manchikanti et.al, p.9, 2012). Such evidence
suggests that profiting from the sale of Opioids was given more importance by pharmaceutical
companies over people’s life.
The extensive marketing and promotion of the Opioids by the pharmaceutical companies
have resulted in increased sales of Opioids (Zee, 2009). Los Angeles Times investigated
aggressive marketing strategies of Purdue Pharma, make of OxyContin, how they mislead
doctors about the longer pain relief which was longer and better then the competitors in the
market. A research published in Jama Internal Medicine inspected the relationship between
Pharmaceutical companies providing meal to physicians and staff comparing it with the amount
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of their product being prescribed. The findings of the study highlights that as the number of
meals being provided by a pharmaceutical company to a physician and their staff increased,
physicians tend to prescribe more of their product (Lopez, 2018).
A pharmaceutical company ‘Purdue Pharma’ which have been given a lawsuit by New
Mexico along with several other states was recently uncovered about the knowledge of its
Opioids being abused and misused. Despite the company’s knowledge about one of its product
‘OxyContin’ which was crushed and snorted for narcotic use, Purdue Pharma still promoted it as
less addictive (Meier, 2018). Such aggressive advertising to promote the brand and persuading
doctors to prescribe highly addictive, dangerous opioids, have turned patients into drug addicts
for pharmaceuticals corporate profit (Hallinan, 2017, p.5). The role played by Pharmaceutical
companies throughout the late 1990s aimed at taking people’s pain and suffering away did the
opposite. Large number of people have lost their lives, and more lives are threatened due to
similar practices of Pharmaceutical companies.
Role of clinicians. Physicians played a significant role in prescribing Opioids in large
amounts since the late 1990s, mainly to relieve their patients from pain. This led to increased
availability of prescription Opioids throughout the last decade, resulting in more people getting
addicted to the drugs. When they couldn’t afford or access prescription Opioids, they turned to
Heroin, a cheaper alternative readily available on the streets of New Mexico. In New Mexico,
clinicians inappropriate prescribing practices caused the deaths of large number of New
Mexicans. Many patients who were prescribed Opioids are either addicted to them or have
overdosed on them or shifted to Heroin.
Because of the lack of alternatives to Opioids for relieving pain, it was understandable for
physicians to prescribe Opioids. However, the problem arose due to lack of physician training,
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prescribing high dosage and their inability to identify other risk factors among the patients which
make them more vulnerable to abuse, addiction and eventually overdose death.
Socio-economic factors and the dire health situation of New Mexicans. New Mexico
is among the states which suffers from interrelated and complex socio-economic problems such
as poverty, unemployment, fewer job opportunities, alcohol and drug abuse, mental health
disorders, homelessness, and high crime rate. It is imperative to highlight that people with
addictions often have other medical conditions, including mental health issues, along with a
variety of socioeconomic problems such as joblessness, homelessness, and family turmoil.
(Lopez, 2018). The crisis is not only fueled with high prescribing rates by clinicians or
pharmaceutical companies’ aggressive strategies, but other socioeconomic factors in New
Mexico are also contributing to the crisis and making the situation worse.
A study concluded that opioid-related decedents had multiple substances in their blood at
the time of death. Alcohol is the most predominant element found more frequently in opiate (i.e.,
heroin and opioid) deaths than any other substance. The study also emphasized on the fact that
causes of deaths are multifactorial, due to physicians prescribing behaviors along with patient’s
non-medical use patterns and systematic failings (Cochella, Dasgupta, Fakata, Fine, Fishman,
Peppin & Webster, 2011).
Similarly, a paper titled ‘Prescription Opioid Abuse in Chronic Pain: A Review of Opioid
Abuse Predictors and Strategies to Curb Opioid Abuse’ identified several risk factors which are
contributing to opioid abuse and misuse. Important factors highlighted include inability of
physicians to identify at-risk pain patients, family history of drug and substance abuse, high
levels of pain disability among patients and unemployment. Likewise, the prevalent of
Prescription opioid use disorder tends to be more among, incarcerated population, cigarette
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smokers, male and white race, people with posttraumatic stress disorder. Self-reported cravings
also cause the misuse of prescribed opioids (Sehgal, Manchikanti & Smith, p.71 2012).
New Mexico’s crisis presents a similar picture where the presence of most of these factors
highlighted above are fueling the epidemic. Family history of addiction, abuse of alcohol (80%
drug abusers abuse alcohol), unemployment, poverty, high incarcerated population, high
percentage of people with Post Traumatic Stress Disorder and high drug supply, along with many
other factors, are constantly leading to an increase in overdose death rate in the state.
Impact of Opioid and Heroin Epidemic in the State of New Mexico
New Mexico is among the states where prescription opioid and heroin related mortality is
a major concern. In 2012 there were twelve states in the United States that had more opioid
prescriptions than it did citizens and New Mexico is among one of them (Nolan & Amico 2016).
The state’s comparison with the nation in terms of drug overdose death rate presents an alarming
picture.
Emily Kaltenbach, state director, Drug Policy Alliance (DPA) stated in the New
Mexico’s state legislature interim committee’s report that “Prescription drugs and Heroin are the
primary causes of overdose deaths nationwide and in New Mexico” (NM GOV, 2017). Policy
reforms in the state are needed to be approached thoughtfully and changes in the current
practices are needed in the state more than ever so that the issue of Prescription Opioids and
Heroin abuse and addiction leading to mortality can be dealt with.
Figure 3 below, illustrates that there has been a constant increase in the drug overdose
death rates in New Mexico from 1990 to 2016 (an increase from 7.7 deaths per 100,000 people
in 1990 to 24.8 deaths in 2016). On the average, the United states death rate increased from 3.4
deaths per 100,000 people in 1990 to 16.3 deaths (NMDOH, 2017). Preventing opioid abuse and
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continuing the need for treatment along with controlling the supply of illegal opioids particularly
Heroin and Illicitly manufactured fentanyl is important in order to curtail the crisis (Aleshire,
Gladden, Rudd & Zibbell, 2016). The trend over the last few decades highlights the severity of
the issue and similarly expresses the need for addressing the epidemic of drug overdose deaths
caused by Prescribed opioids and Heroin.

Figure 3: Drug overdose death rates, US vs NM 1990-2016
Retrieved from database of New Mexico Department of Health, New Mexico Indicator-based information
system, 2018

In 2015, New Mexico was ranked 8th in the nation for highest percentage of drug overdose
deaths going down significantly from 2nd throughout the nation in 2014. The most recent ranking
for 2018 by CDC shows New Mexico ranked 12th in the nation in terms of overdose deaths rates.
(CDC, 2018). Implementation of several programs throughout the state and enacting new policies
and interventions played a major part in the decline in the ranking for overdose deaths in New
Mexico.
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On the other hand, some argue that New Mexico hasn’t done much to deal with the crisis.
Despite being recognized as a frontrunner in the nation in implementing effective policies, New
Mexico still needs to show progress in achieving the trend of decreasing overdose and related
deaths. New Mexico’s problem to Opioid abuse and addiction should be dealt with highest priority
and much reforms are needed at the community, local and state level.
Impact on different New Mexico counties. According to ‘New Mexico Substance
Abuse Epidemiology Profile’, Bernalillo county has highest number of drug overdose deaths
with 923 deaths in total from 2012 to 2016. Total number of deaths in New Mexico from 2012 to
2016 has a staggering figure of 2,465 deaths. This means that in 1,825 days, 2,465 people died in
New Mexico due to drug overdose. (NMDOH, 2017). Simply, there has been a drug related
fatality in New Mexico every 18 hour.
Rio Arriba County also considered as a heroin capital of the country had highest drug
overdose death rate (85.8 deaths per 100,000) during 2011-2015. This county has seen the
problem of Opioid addiction decade before the entire nation. Overdose deaths in the New
Mexico county with the highest death rate (Rio Arriba) were 89.9 deaths per 100,000 population.
However, New Mexico’s rate (24.8) continues to remain higher than the most recently
announced national rate (16.3) per 100,000 population reported for 2016. (NMDOH, 2017).
It is important to draw attention to the fact that despite higher age adjusted death rates,
the total number of deaths need to be taken into consideration when prioritizing resource
distribution or policies enaction. For instance, Rio Arriba county may have highest death rates on
average, but Bernalillo county with high population percentage and more overdose deaths
number might get more resources and funding to deal with the crisis than Rio Arriba county.
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Impact on gender and specific ethnicities. According to a report by Department of Health
(2017), Hispanic population have the highest number overdose deaths at 26.9 deaths per 100,000,
followed by Whites at 23.6 deaths and Blacks with 22.6 deaths per 100,000. Asian and Pacific
Islanders have the least amount of overdose deaths among all ethnicities in New Mexico with
averaging 5.7 deaths. Approaching the problem by keeping different ethnicities in mind would
help provide better resource allocation and effective policy making in terms of dealing with the
problem.
Table 1 below derived from New Mexico’s substance abuse epidemiology report from
2017, present the figures from Office of Medical Investigator’s data on unintentional overdose
deaths from 2012 to 2016. The data categorizes male, female, along with type of drug involved
that is prescribed or illicit. With the actual numbers, the graph below shows the average rate and
provide comparisons among different categories of drugs involved in overdose.

Table 1: Unintentional drug overdose deaths and rate among genders in New Mexico, 20122016

Retrieved from New Mexico Substance abuse epidemiology report (2017); OMI death files; UNM-GPS
population files; SAES
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It is important to recognize the limitations that are attached with the numbers because
these categories are mutually exclusive and determining the exact drug causing the fatality is not
easy due to involvement of more than one substance. It is also vital to acknowledge that to craft
appropriate policies, it is imperative to determine whether the overdose is either due to
prescribed or illicit Opioid. For instance, policies can be established looking at the factor of only
blaming oxycodone as a culprit in overdose deaths, but the death might have been caused by
illicitly manufactured Fentanyl.
This approach will help policy maker and other stakeholders in ensuring that enough
resources are diverted towards law enforcement in dealing with the issue of controlling the
supply of illicitly manufactured Fentanyl rather than limiting the number of prescribed pain
medication for terminally ill patients who without the medications, would have a higher tendency
to switch to illicit opioids like heroin.
Figure 4 below illustrates the number of Opioid related fatalities looking specifically at
Heroin, Synthetic and Prescribed Opioids. It highlights the trends from 1999 to 2016 showing
that prescription opioids related death increased throughout from 1999 and peaked in 2014 at 257
deaths but since then has been on a decline with the figures of 2016 showing 186 deaths in New
Mexico caused specifically by prescribed Opioids. Heroin on the other hand has seen a spike in
the recent years and the graph shows the highest number of deaths involving heroin surpassed
previous years death with 161 deaths in 2016 alone.
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Figure 4: Overdose Deaths involving Heroin, Synthetic Opioids and Rx Opioids New
Mexico 1999-2016
Retrieved from National Institute of Drug database (2018)

Prescription Opioids is a major cause for this epidemic in New Mexico. According to
New Mexico Department of Health (2017), 53% of drug overdose deaths involved Prescription
drugs, 33% involved illicit drugs along with 14% involving both types. The most common drugs
as indicated by Medical examiner data were prescription opioids (e.g., methadone, oxycodone,
morphine 48%), heroin (34%), tranquilizers/muscle relaxants (23%), cocaine (17%),
methamphetamine (16%) and antidepressants (12%) (not mutually exclusive) (NMDOH, 2017).
Deaths caused by Heroin as well as synthetic Opioids has seen a surge in the recent years
causing significant numbers of overdose deaths in the state of New Mexico. The number of
overdose deaths caused by heroin slightly increased from 2015 from 156 deaths to 161 deaths in
2016. National Survey on Drug Use and Health in 2014 and 2015 estimates the number of past
year heroin users among New Mexico adults to be 3,000. Interestingly, 9,649 people enrolled in
the department of health’s syringe services program in 2016, where 6,976 people indicated
heroin use(Gallagher, 2018). The estimates clearly suggest that number of heroin users are
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miscalculated, and it is important to identify the right numbers in order to incorporate right
policies and interventions to deal with the heroin crisis.

Interventions to Curb Prescription Opioid and Heroin Crisis in New Mexico:
Policy Analysis
This section will evaluate the effectiveness of current state policies and other intervention
within the state along with identifying and assessing policies implemented in other states and
countries which can benefit New Mexico’s situation. It will focus on the results of findings and
will provide the decision makers with the recommendations in terms of effective policies that
will work towards eliminating the plague of Prescription Opioids as well as Heroin abuse in state
of New Mexico.
In 2015, news accounts related to prescription painkillers and heroin abuse were as
abundant as stories relating to Climate change, Ebola and Measles (Wallis, 2016). President
Obama addressed the issue of Opioid abuse with expansive policy reforms and new measures
meant to combat harms caused by opioids, including $1.1 billion in future funding. (Fazio,
2017). Trump administration in late 2017 declared Opioid crisis a public health emergency, since
then, major agendas of the administration focused on stopping china for illegal drug trafficking
and a developing a vaccine for addiction which is still in its early stages. It is fair to argue that
with almost a year since the new administration declared opioid crisis a national emergency,
nothing significant has been done at the federal level to deal with the crisis.
Looking back on the crisis in the state, New Mexico state legislature provides
information regarding the legislations which were implemented in the state along with those
which were not executed. With the help of the data, this section will focus on studying current
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state policies, monitor some significant interventions and will offer recommendations to achieve
the over-arching goal of reducing the overdose deaths caused by prescribed pain relievers and
Heroin.
New Mexico State Legislations to Address Overdose Deaths caused by Prescription Opioids
and Heroin
It is important to acknowledge the reforms in state laws which are focused on improving
healthcare and physicians’ practices regarding prescribing Opioid medication while also keeping
the aspect of allowing Opioids for effective pain management. New Mexico state legislature
mandated several policies to address the issue of prescription Opioid and Heroin abuse and
addiction.
Senate bill 263: opioid prescription monitoring (52nd legislature - state of New
Mexico - second session, 2016, introduced by: Richard C. Martinez). With the
implementation of this bill in the state, prescription monitoring programs (PMPs) were modified
and strengthened to better address the issue of prescription Opioid abuse in the state of New
Mexico. Starting 2017, the state mandated all prescribers to have access to the data base and
integrate the system in all clinical settings around the state. New Mexico is among the only two
states, that ensured all 6 measures which National Safety Council highlighted as important aspect
to deal with the crisis of opioid overdose deaths. Strengthening PMPs was one of those aspect
which was addressed with the passing of senate bill 263.
PMPs and how they work in New Mexico. An online electronic data base system
administered by New Mexico Board of Pharmacy tracks the dispensing and prescribing of
controlled substances. PMPs enacted in New Mexico’s first started collecting data beginning of
2005. PMP provides practitioners, pharmacists and other authorized user with the ability to
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review patient’s history with the main emphasis on preventing overdose deaths, abuse and
addiction caused by controlled substances. Supported by evidence, prescription drug monitoring
programs (PMPs) reduce the amount and number of drugs prescribed, particularly opioids
(Chang, 2016; Fisher, 2012; Rasubala, 2015; Rutkow, 2015 & Wastila, 2012)
In New Mexico, all laws and regulations concerning the PMPs are administered and
enforced by New Mexico Board of Pharmacies. Prescribers can register online and access patient
reports containing the history of medications which the patients had and are currently using.
Reports help in identifying ‘doctor shopping’, help evaluate therapies, monitor compliance with
patient treatment agreements (contracts), along with recognizing possible altered prescriptions
(NM Board of Pharmacy, 2015).
New Mexico is among the states that mandates all prescribers to register with the PMPs.
This resulted in a significant change in term of prescribing practices. Evident by research states
which have effectively implemented prescription monitoring programs within their vicinity
appears to have smaller increases in opioid misuse along with fewer opioid related hospital
admissions per year compare to states without prescription monitoring programs (Reifler 2012
& Reisman 2009).
New Mexico Department of Health’s overdose prevention first quarter of 2018 shows
that total number of controlled substance patients in New Mexico for the first quarter of 2017
were 274,956 which reduced to 253,069 by the first quarter of 2018. Report also shows that
number of people receiving Opioids also declined by 9.9% from 191,173 to 172,187 patients in
2017 and 2018 respectively. (NMDOH, 2018).
House bill 277: administration of Opioid antagonists (52nd legislature - state of New
Mexico - second session, 2016); Senate bill 262: administration of Opioid antagonists (52nd

20

legislature - state of New Mexico - second session, 2016) & House bill 370: Opioid overdose
education (53rd legislature - state of New Mexico - first session, 2017). The amended section
of bill mandates that Opioid treatment centers must provide the patients with education regarding
Opioid abuse and overdoses, as well as educate patients on the use of naloxone (opioid
antagonist). It also ensures that inmates diagnosed with opioid use disorder at correctional
facilities shall be provided with Opioid overdose educations as well as doses of naloxone along
with the prescription for naloxone at time of release from correctional facility. The bill also
mandates that all law enforcement officers shall carry naloxone all the time when on duty to deal
with overdose incident. New Mexico became the first state to pass such legislation in the
country.
New Mexico house bill 370 ‘Opioid Overdose Education’ which became effective of July
1, 2017 is the first highly tailored naloxone legislation in the United States aimed at reducing
drug overdose deaths by targeting those populations that are most likely to be affected (Katzman
et al.., 2017). It is also important to evaluate the effectiveness of this legislation to fully
understand the impact on patients and societies across New Mexico.
Figure 5 below show the most recent data of the impact of naloxone legislation in the
state. There has been a constant increase in the dose distribution which is part of New Mexico’s
department of health ‘Harm Reduction Program’ service. The number increased from 1,948
counts of doses in the first quarter of 2017 to 8,080 counts in 2018 (NMDOH, 2018).
Enrollments in such programs also saw an increase in the state and the number of reported
reversals from naloxone also saw a slight increase. Similarly, increasing distribution of naloxone
alone will not solve the overdose death problem and with high cost and lower shelf of naloxone,
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it can become expensive for a state like New Mexico with limited resources to afford such
expenses.

Figure 5: Naloxone Enrollees, Doses and Reversals, 2017-18
Retrieved from NMDOH overdose prevention quarterly measures report (2018Q1)

Senate bill 215: pain management advisory council changes (50th legislature - state
of New Mexico - second session, 2012). This bill signed into law in 2012, brought several
changes specifically at containing prescription Opioid abuse in the state of New Mexico. One
aspect of the bill is the creation of ‘Prescription drug Misuse and Overdose Prevention and Pain
Management Advisory Council’ working for New Mexico Department of Health to provide state
with recommendations of tackling the issue. The second aspect of bill mandates the requirement
for continuing prescriber education for treatment of non-cancer pain management which will
help prevent the crisis in future with better prescribing practices.
House memorial 56: study heroin-assisted treatment (53rd legislature - state of New
Mexico - second session, 2018, introduced) & Senate joint memorial 15: study efficacy of
naprapathic medicine (53rd legislature - state of New Mexico - second session, 2018). State
of New Mexico over the past few years have been working diligently to address the prescription
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Opioid overdose deaths. This memorial is an example where the state has shown desire to look
for alternative method of treatments other than Opioids to deal with pain. Several other agendas
have been considered in the state legislature including, House Memorial 61 which calls for
February 23rd as ‘ChoosePT’ day where state emphasized on ‘Physical Therapy’ and the role
therapist play in decreasing Opioid addiction by using therapy to manage pain rather than using
Opioids.
Failed Legislations
Several legislations were introduced over the last decade to address the prescription
Opioids and Heroin abuse/addiction in New Mexico which were not taken into consideration by
the state. Some significant failed legislations worth mentioning includes:
House bill 241: Opioid abuse prevention & assisted treatment (52nd legislature state of New Mexico - second session, 2016). One aspect of the bill calls for a clause stating
health insurers ‘shall provide coverage for at least one abuse-deterrent Opioid for each Opioid
analgesic active ingredient’. The expenses on naloxone or distribution of antidote can be
reduced, if health insurers are brought on board to provide at least one-abuse deterrent. The
passage of this legislation would have allowed the correctional facilities to intervene with those
population segment, who alternatively would not have opted for the treatment. Having the
correctional facilities providing medicated-assisted treatment could have potentially benefited
the state since the existence of opioid use disorder is high among incarcerated population in New
Mexico.
House bill 294: reclassify dihydrocodeinone as schedule ii (52nd legislature - state of
New Mexico - first session, 2015). New Mexico currently considers Hydrocodone as schedule II
drug, but the combination of this drug with other ingredients are included to be a part of schedule
III. Though FDA reclassified the combinations of Hydrocodone as a schedule II drug, the
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implementation of this bill would have aligned New Mexico with the Federal Controlled
Substance Act. Hydrocodone is among the most frequently prescribed drug because of which it
has high tendency to get abused. “In 2004, the United States used 99% of the global supply of
the Opioid hydrocodone, according to the 2005 report from the International Narcotics Control
Board” (Manchikanti, 2007). Such prescribing practices provides a matching picture of how
increased prescribing lead to higher overdose deaths over time.
Prescription Monitoring Programs in the state have played an astonishing role in reducing
the amount of prescription medications dispensed. However, the state needs to invest in and
consider options for controlling drugs that have higher potential for abuse and are responsible for
high number of deaths. Legislations similar to HB 294 should be considered vital in terms of
dealing with Prescription Opioid crisis in the state of New Mexico.
Impact of Legislations
There has been a stability in the rate of overdose death rates in the state since 2014 which
can be attributed to implementation of several state and federal guidelines, laws, regulations,
along with education and advocacy programs. Prescription Monitoring Program, broader access
to medicated assisted treatments, naloxone program and other prevention strategies are playing
significant role in addressing the State's opioid crisis.
In the most recent reports from New Mexico department of health, there is a 5% decline
in Opioids prescribed in the state with 63% of providers using prescription monitoring program.
With the implementation of stronger prescription laws, 'doctor shopping' saw a significant
decline. The number of patients with overlapping Opioid prescriptions from different prescribers
decreased by 13 percent from 2016 to 2017 (NMDOH, p.2, 2018).
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Controlling prescription medication has been considered a well-played tactic to reduce
overdose death rates in New Mexico but it is important to acknowledge that the process takes
time. 2016 mortality data shows a slight increase of overdose death from 493 to 497 in 2016 with
the increase in population as well as maintaining the average rate to be at 24.8 deaths per
100,000. The governor of New Mexico also became the first in the US to sign the law, making
law enforcement officers to carry naloxone on duty and requiring pharmacists to dispense this
drug without prescription.
Recommendations
Enaction of several legislations and state level interventions including the implementation
of prescription monitoring programs across all clinical settings, legislation to fund the widedispensing of the Naloxone along with requiring law enforcement to carry naloxone, as well as
aiding those seeking help from opioid use disorder to be free from involvement in criminal
justice system have been effective strategies considered by the state.
Despite the efforts, New Mexico still suffers from higher number of fatal overdoses and
the legislature continues to receive extensive testimony from residents and health and social
service providers regarding the problem and how the insufficiency of vital resources to meet the
demand resulting from the problem is affecting the communities (Ruiloba, 2018). The current
scenario presents a need for an effective policy intervention.
This section provides recommendations for the policy makers to introduce certain laws
into the legislature along with certain evidence-based practices implemented in other states and
countries which, if implemented in New Mexico might help tackle the crisis. By using strategic
planning technique for assessing the Strengths, Weaknesses, Opportunities and Threats (SWOT)
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of possible policies and interventions, introduction of proposed measures will be justified. This
will help create the roadmap for addressing the crisis in the state of New Mexico.
Creation of New Mexico’s Prescription Opioid and Heroin Action Team
New Mexico is among the state where the state does not mandate the use of any specific
body tasked with addressing the problem of prescription opioid and heroin abuse and addiction.
The need for a separate entity tasked specifically to target the issue of prescription opioids and
heroin crisis is important to curb the problem.
House Memorial 12 (Died) in 2018 regular session introduced by Patricio Ruiloba
highlighted the current opioid related issues in the state and highlighted, “there is no single entity
that bears the responsibility for leading and coordinating the state’s response to opioid use
disorder crisis”. The memorial suggested the need to create an “opioid crisis subcommittee” to
address the crisis and make recommendations to the legislature by the end of year 2018 (NM
GOV, 2018). Creation of an action team working specifically towards eliminating the crisis
similar to Governor Kasich of Ohio’s team might prove beneficial for New Mexico.
Governor Kasich of Ohio in 2011 created Governor’s Cabinet Opiate Action Team which
implemented several multi-faceted strategies to deal with high overdose deaths in the state of
Ohio. Similarly, King County in Washington convened a task force named ‘Heroin and
Prescription Opiate taskforce to address the rising fatalities caused by these licit opioids and
Heroin in the county. The taskforce in king county published the report in 2016 emphasizing on
long and short-term strategies to avert opioid use disorder, overdose, along with enhancing
access and other supportive services for those facing the crisis (p.1).
New Mexico can follow the footsteps of Ohio’s Opiate Action Team, as well as King’s
County, Seattle, ‘Heroin and Prescription taskforce’. The team can be solely responsible in
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promoting responsible opioid use, prevent addiction, reducing the number of fatal overdoses, and
improve treatment access to all underserved areas and other supportive services for individuals
experiencing OUD.
The role and responsibilities taken up by the task force can include, but not limited to the
table below.
Table 2
Role of New Mexico’s Prescription opioids and Heroin crisis Action Team
Prevention
•
•
•
•

Expansion of Medicatedassisted Treatments

Raise Awareness of the
adverse effects including •
overdose
Identify OUD through PMPs
at early stages
•
Youth drug Prevention
Promotes safe storage and
Disposal
•

Data Driven solutions to
deal with the Epidemic
•
•
•

Using technology and data to
study the future trends
Ensuring that data is shared in
real time across all
departments
Model of Telesphora.

Expand Access to Naloxone
for Overdose prevention

Ensuring and promoting use •
of Buprenorphine along with
methadone to all underserved
areas of NM
•
Implement evidence-based
treatment strategies including
HAT and Oversee supervised•
consumption sites (SCS)
Work on eliminating
logistical and political
barriers in terms of getting
people treatment access.

Aim to reduce overdose
deaths with naloxone
distribution
Aware community of
naloxone uses and access
points
Evaluate the effectiveness

Lead efforts to curb Heroin
and Rx abuse partnering with
Department of Health;
Department of Public Safety;
Board of Pharmacy; Insurers;
etc.

Identify more evidencebased solutions to address the
Epidemic in the state and
report directly to state
legislature every 6 months
about the accomplishments
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Additionally, the task of Action team could implement data-driven solutions with the
help of machine learning, specifically for prevention, treatment and the usage of opioids (Three
of five main agendas of HHS). Using model similar to Telesphora, where the team used a unique
blend of human-centered design working with big data to create a platform that uses real-time
open-access data and machine learning to predict the occurrence of future mortalities in New
Haven, Connecticut (Lindberg, 2018). The task force can follow the example of such model to
focus on preventive strategies through predicting future trends to avoid overdoses and better
ambulatory services which might prevent future overdose deaths.
New Mexican Doctors can Beat the Opioid Epidemic (ALTO)
With 42 percent of visits to Emergency Departments (ED) being attributed to pain,
the ED could be an efficient and effective venue for reducing and preventing the amount of
opioid related overdoses, while also reducing the strain these visits create on the health care
system (Cantrill et al., 2012; Noble et al., 2007). As highlighted earlier, from 2012 to 2016,
there has been a constant rise in the emergency department visit in the state of New Mexico
related to Opioids. Emergency departments can be an important venue for doctors to address
the issue, since they are considered as a starting point for a path to opioid addiction and
abuse.
Emergency Department dataset is collected in New Mexico in accordance with the
state law. Looking at the data from New Mexico’s Substance Abuse Epidemiology report,
Table 3 below illustrates the opioid-related emergency department visit within the state
between 2012 and 2016.
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Table 3: Opioid Overdose Related Emergency Department Visits and Rates* by
Race/Ethnicity and County, New Mexico, 2012-2016

Source: NMDOH BVRHS death files and UNM-GPS population files; SAES

One example of how the venue of EDs in New Mexico can be used to curb the prevalent
of opioid abuse is by adopting the model of Saint Joseph’s Medical Center in Patterson New
Jersey known as ALTO (Alternative to Opiates Program). The program initiated in 2016 aimed
at reducing the Opioids use by using alternative treatment methods. Some of these included:
treating back pain patients with trigger-point injections, providing ultrasound-guided nerve
blocks for bone-fracture patients, and also treating patients with kidney stones by using methods
not requiring the use of opioids to tailor patients’ pain management needs (ALTO, n.d). This
presents a successful example of introducing alternative to Opioids medication and treatment
methods that can be adopted to reduce the use of Opioids.
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The ALTO initiative resulted in the reduction of use of Opioids medication by 38 percent
in just five months and treated over more than 300 patients using the above-mentioned
alternative ways of treating pain with significant results at the success rate of 75% at Saint
Joseph Medical Center (ALTO, n.d). The hospital not only focused on reducing the use of
opioids while treating acute pain during the visits but also worked on several multifaceted
strategies like connecting patients with physical therapy and pain management specialists to
work on stopping acute pain becoming a severe one.
Looking at the dataset in figure 7 regarding emergency department visits related to
opioids, from 2012 to 2016, there were 6928 visits it total. There has also been an increasing
trend over the past few years from an average increase of 48.2 visits per 100,000 people in 2010
to 76.7 visits per 100,000 in 2016 (NMIBS, 2018). The venue of emergency departments for
Hospitals in New Mexico can implement ALTO model within the healthcare setting. This can
only be made possible if physicians are trained enough and are determined to reduce the opioid
abuse and addiction in the state.
Following the success of ALTO in New Jersey, ALTO has also been praised by both state
and national level with “Two new bipartisan bills in Congress are highlighting it as well, aiming
to set up a nationwide demo and study the results” (Khemlani, 2018). Policy makers in the state
can direct the state department of health study the model of ALTO and ensure such methods and
guidelines are implemented in the emergency department all over the state. This can be done by
bringing emergency department medical directors, physicians’ group, pharmacist and healthcare
administrators on board. Implementation of ALTO will help the cause of preventing opioid use
and will eventually help bring the number fatalities caused due to prescribed opioid down in
future.
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Implementing such programs comes with certain limitations. One problem is health
insurance companies not willing to pay for non-opioid medications and the bigger problem is
patients do not want to pay out of pocket for the medications. Importantly, physicians are not
trained enough or does not have desire and willingness to spend more time on patients due to
busy Emergency departments as well as incapability of healthcare organization to implement the
model of ALTO due to scarce resources (limited physicians). Such limitations are needed to be
addressed by the people in authority and programs like ALTO must be implemented across
healthcare setting in New Mexico in order to contain the epidemic of fatalities caused by
Prescribed Opioids.

Table 4
SWOT Analysis: Alternative to Opiates Program (ALTO)
Analysis Objectives: The objective of this SWOT analysis is to highlight the implications of
alternative to Opiates strategy as implemented by Saint Joseph’s Medical Center in Patterson
New Jersey. The analysis will suggest whether ALTO can be an effective approach for
reducing Prescription opioid and heroin abuse eventually leading to fewer overdose deaths in
future, if implemented across Emergency departments in New Mexico.
•
•
•
•

Strengths
Using non-opioid methods to relieve pain at
Emergency Departments in hospitals would
lead to less abuse and addiction to opioids
Prevent fatal overdose due to prescription
opioids
Venue can be used to raise awareness about
opioid addiction
Can prevent acute pain from becoming a
chronic pain without opioid dependency

•
•
•
•

Weaknesses
Health insurers will not pay for non-opioid
medication
Patients not willing to pay for out of pocket
medication costs
Healthcare Emergency Departments not
equipped with enough trained physicians
Limited willingness of physicians and
Emergency department staff
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•
•

•
•

Opportunities
Since the model is under consideration at •
federal level, funding to initiate ALTO in NM
can be secured
Considering high societal, economical costs •
of opioid abuse, implementing ALTO model
in Emergency departments would still be cost•
effective
As the program matures, addressing chronic
pain can be the next step without opioid
dependency
Less use of opioids will lead to less insurance
costs, since they won’t be paying for
expensive medications at emergency
departments

Threats
Illicit drug supply will always be a threat,
because consumption of Opioids cannot be
controlled outside the emergency departments
Health insurers and Pharmaceutical
companies might not come on board
Patients not agreeing to ALTO methods of
treatment and their preference for opioid
prescription might impact the effectiveness of
this intervention

Analysis
Emergency Departments across New Mexico can follow the footsteps of Saint Joseph’s
Medical Center by implementing measures like ALTO within the healthcare settings. Looking
at the analysis, it is evident that New Mexico can benefit from the implication of such
measure. Despite some limitations, implementation of ALTO can benefit New Mexico in
dealing with the crisis.

Heroin Assisted treatments (HAT)
Medicated-assisted treatments are considered as promising evidence-based approach in
which medications along with behavioral and counselling therapies are provided to tackle opioid
abuse and addiction. “In New Mexico, an annual average of about 3,000 individuals aged 12 or
older (0.18% of all individuals in this age group) in 2014–2015 had used heroin in the past year”
(SAMHSA, 2017). Another recommendation, which has been introduced in the state of New
Mexico’s 2018 legislative session in form of Memorial, is studying the effectiveness of Heroinassisted treatments which proves to be an effective strategy to deal with heroin crisis. Such
treatments have been implemented in many countries like Switzerland, Canada, Germany,
Netherlands and Denmark.
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A paper published in The British Journal of Psychiatry ‘Heroin-assisted treatment for
Opioid Dependence: Randomized controlled trial’ by Christian Haseen, Uwe Verthein, Peter
Degkwitz and Juergen Berger, conducted largest randomized control trial comprising of 1015
people, where the results suggested that such treatments prove to be more effective for those with
opioid dependence and continue using heroin while being treated at other medicated assisted
treatments (methadone). They also emphasized that despite risks, it should be considered for
treatment under medical supervision (Haseen, et al.,2007). New Mexico’s overdose death rates
caused by Heroin are increasing every year and so there is an urgent need to fight Heroin
addiction under medical supervision.
House memorial 56 titled ‘Study Heroin Assisted-treatments’ introduced by Deborah
Armstrong in a recent state legislative session provided the snapshot of the severity of Heroin
abuse and addiction along with the fatalities, which according to National Institute of Drug
Abuse were 161 in 2016. It also emphasized on how similar treatments in other parts of the
world brought improvements in terms of dealing with the overdose death rates related to Heroin.
Heroin assisted treatments can be a good initiative in New Mexico, following the
footsteps of certain European countries along with Canada. Several of these countries launched
safe injection sites, where injectable medical grade heroin is provided to those struggling with
Heroin addiction. United States does not allow Heroin Assisted Treatment practices within its
boundaries, but the current crisis situation in the United States and New Mexico demands
different measures. Heroin Assisted Treatments for those patients where other methods of
treatment have failed, might prove to be an effective strategy and by considering such measures,
New Mexico becoming the first state to implement such practices can set an example for other
states to follow in order to curtail heroin overdose deaths.

33

Wim van den Brink, a professor of psychiatry and addiction at the University of
Amsterdam, Netherlands highlighted the results of several studies conducted in conjunction with
using heroin as a method of treatment for patients where other methods of treatment has failed.
Supervised heroin consumption is considered feasible, safe, and effective option for brining
improvements in physical health, mental status, and social functioning along with reduction in
criminal behaviors (Van Brink, et al., 2003). The studies also highlighted the benefits derived
from Heroin assisted treatments in terms of reducing stigma associated with heroin as well as
being cost effective.
Treating heroin addiction without the stigma can prove to be beneficial for New Mexico
in order to deal with the overdose death crisis. In the past, heroin addiction has been stigmatized
and tabooed. Embracing medication-assisted treatments recently shows that society is now
looking at the problem differently. Addiction is now considered as a medical condition instead of
a moral failure (Lopez, 2017). Treating addiction with acceptance in the society, under medical
supervision and by providing safe injection sites, state can provide heroin addicted patients with
treatment access, that might lead to fewer overdose deaths caused by Heroin in New Mexico.
The state of New Mexico desired the need to study the effectiveness of such heroin
assisted treatment centers in the recent state legislative session introduced by Deborah
Armstrong. Initiating Heroin-assisted treatments at all state-funded treatment centers (MAT)
might prove beneficial to curb the rising overdose deaths in the state as highlighted by a study
conducted in Germany. The researchers conducted a 2-year study where 515 participants
addicted to Heroin were treated with medical grade heroin. 278 people over the period of 24
months were retained which is 54.8% retention rate. The results of the study suggest that Heroin
Assisted treatment were associated with long term improvements in physical as well as mental
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health and also lead to reduction of illicit drug use along with higher retention rates ( Bonorden‐
Kleij, Degkwitz, Dilg, Haasen, Köhler , Passie, Soyka , Tanger & Vogel, 2008). If such
treatment measures were adopted in the state, some of the overdose deaths caused by heroin
could have been avoided.
There are several limitations that can reduce the effectiveness of Heroin Assisted
Treatments (HAT) and might affect the acceptability of the initiative at state level. One
limitation is the loss of treatment benefits after the end of treatment. A recent study conducted in
2016 examined the implications on patients who were provided one year of heroin assisted
treatment. A follow-up study was conducted three months after the end of treatment to identify
whether the benefits have sustained or not. The results of the study suggest that end of HAT lead
to increased use of street heroin among patients (Ansseau, Charlier. Deblire, Demaret, Dubois,
Lemaitre, Litran, Magoga Quertemont, 2016). This limitation might create hurdle in introducing
such measures at the policy level in New Mexico.
Another study conducted in Switzerland by Franziska Güttinger & Patrick Gschwend in
2003 followed up on a six year long Heroin Assisted treatment. Despite some benefits
highlighted by the authors, the results of the study “showed an increase in unemployment and
reliance on social benefits” (Gschwend & Guttinger, 2003), among those who were treated at the
heroin-assisted treatment centers. Looking at it from a policy maker’s perspective, it is important
to weigh all the costs and benefits associated with the introduction of HAT in New Mexico.
SWOT analysis below provides a picture of how the implication of Heroin Assisted
treatments in New Mexico would benefit the state in order to curtail the issue of Heroin Abuse
and Addiction. It highlights the strengths that will be the benefits derived with the introduction
along with opportunities which will further support the implication of HAT across New Mexico.
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The analysis also provides the snapshot of weaknesses (negative factors that might hinder
adaptations of the measure) and threats (external factors that might negatively affect the
introduction of such intervention) associated with the introduction of HAT. Investing resources
to consider the initiative as a pilot program in Rio Arriba county, where average overdose drug
deaths is four times more than the average deaths of New Mexico, might prove beneficial for the
state in curtailing the overdose deaths. If the intervention has positive results, it can be expanded
across whole state.
Table 5:
SWOT Analysis: Heroin Assisted Treatment
Analysis Objectives: The objective of this SWOT analysis is to highlight whether the
introduction of Heroin Assisted Treatment centers or Safe Injectable Sites across New Mexico
is a feasible, effective and cost-effective strategy for reducing drug use and drug-related harm
among long-term heroin users in New Mexico for whom other treatment programs have failed.

•
•
•
•
•

•

Strengths
Retention Rates in HAT are much higher
•
compare to methadone or other medicatedassisted treatment.
Heroin-assisted treatment reduces illicit drug
use
Heroin-assisted treatment improves health •
and quality of life
•
Heroin-assisted treatment reduces crime
Heroin-assisted treatment is cost effective, in
that the cost-savings from the benefits
attributable to HAT far outweigh the cost of
program operation over the long run
Lead to decline in overdose fatalities caused
by heroin

Weaknesses
A long term study in Switzerland shows HAT
leads to increase in unemployment and
reliance on social benefits in long run.(
Franziska Güttinger & Patrick Gschwend,
2003)
Once study suggested the loss of treatment
benefits once treatment ends after 12 months
Cannot control free heroin-seekers
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•
•
•
•
•

Opportunities
Heroin-assisted treatment can provide
•
opportunities for other treatments including
abstinence
Heroin-assisted treatment can reduce the
•
black market for other illicit drugs along with
heroin
Threat of HIV can be contained with less
•
needle exchange
Reduce the stigmatization attached with
Heroin and people will consider Heroin
addiction as a disease or a medical condition •
Using other evidence-based techniques like
physical therapies, Reiki, Ibogaine etc. can be
implemented alongside with HAT

Threats
Changing political dynamics in New Mexico,
Upcoming legislators might not approve of
the initiative
Illicit drug supply will always be a threat,
because consumption of Heroin cannot be
controlled outside the medically supervised
treatment setting
Federal government still does not approve of
Heroin Assisted treatments, state can face
backlash from Feds
Prescription opioid abuse leading to heroin
will always be a threat, as long as there is Rx
abuse people will initiate heroin

Analysis
Heroin crisis in New Mexico is severe and in 2016 alone 161 people lost their lives due to
overdose on Heroin which has been on a rise since 2010. With stricter prescription laws in the
recent years, inaccessibility to prescribed medications will lead to many people shifting
towards illegal street heroin which will eventually lead to higher overdose deaths in the
coming years. Many studies highlight the benefits that can be derived with the implication of
HAT. To tackle the issue, supervised heroin consumption sites might prove beneficial to avoid
future deaths caused by heroin. Looking at the SWOT analysis, it is evident that New Mexico
can benefit from having Heroin Assisted Treatment centers across the state since the Strengths
and opportunities outweigh the weakness and threats.

Treating Opioid Use Disorder with Medical Cannabis
Senate memorial 55 and House memorial 67 introduced in the most recent legislative
session in 2018 titled ‘Medical Marijuana & Opioid Use Disorder’ have been passed in both
houses of the state where the Department of health has been requested to consider opioid use
disorder as qualifying condition to access medical cannabis. The department secretary denied the
request blaming in on little evidence supporting the positive effects of cannabis on those with the
opiod use disorder (Oxford, 2018). In 2017, New Mexico Governor also vetoed a house bill 537
titled ‘Public Peace, Health, Safety &Welfare Medical Marijuana Changes’ which would have
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considered opiate use disorder as a qualifying condition, stating that Medical Cannabis board
does not have a capacity to enroll large number of qualifying patients to access cannabis.
Despite the measure not approved at the state level, large number of studies highlight the
effectiveness of using cannabis in addressing the problem of Opiate Use Disorder and overdose
deaths. A study ‘Emerging Evidence for Cannabis' Role in Opioid Use Disorder’ articulates that
opioid withdrawal symptoms can be eased with cannabis, it helps in reducing opioid
consumption, reduce cravings, prevent relapse, along with improved treatment retention, and
overdose deaths. (Wiese & Wilson-Poe, 2018). States that have legalized both medical and adult
use cannabis show a significant reduction opioid consumption along with opioid related overdose
deaths. Despite the fact, it is still early to conclude the effects of legalization for adult use since
such the interventions are fairly new and the long-term impact is yet to be studied.
California in 1996 approved medical cannabis which lead to significant decline in opioid
consumption. Marcus A. Bachhuber, Brendan Saloner, Chinazo O. Cinningham and C L.Barry
compared the presence of state medical cannabis laws and Opioid Overdose mortality, the
finding of their study suggested states with medical cannabis laws had a 24.8% lower mean
annual opioid overdose mortality rate compared with states without medical cannabis laws”
(Bachhuber et al., 2014). Mortalities related to opiate use disorder is alarming in New Mexico
and measures to promote the use of cannabis in treating opiate use disorder could play a
significant role in preventing the deaths.
Ian M. Adams, Anthony P. Reeve, Sarah S. Stith and Jacob M. Vigil conducted a cohort
study to highlight the associations between medical cannabis and prescription opioid use among
chronic pain patients in New Mexico between 2010 and 2015. The goal of the study was to
determine the cessation and reduction of use of prescription pain relievers due to enrollment in
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Medical Cannabis Program compared with the other group of similar characteristics but not
enrolled on Medical Cannabis Program (MCP). The result of the study after 21-month
observation indicates that MCP enrollment was associated with over 80% of reduction in
prescription opioid use along with 40% completely gave up opioid use replacing it with
cannabis. (Adams, Reeve, Stith & Vigil, 2017). Lack of research on cannabis is mainly
associated due to federal restrictions and consideration of cannabis as a controlled substance,
despite that this study in New Mexico proves that cannabis can play an important part in tackling
the issue.
Cannabis is associated with reducing the harm and risk of overdose caused by Opioid Use
Disorder and current evidence along with several states opting to consider OUD as a qualifying
condition to enroll for Medical Cannabis suggests that it can be considered as an option. New
Jersey added opiate use disorder to the list of qualifying conditions for enrollment in the state's
medical cannabis program (Wiese & Wilson-Poe, 2018). State of Pennsylvania also followed
New Jersey’s footsteps along with New York and Illinois considering the option as well.
Despite several studies stressing on the benefits of Medical Cannabis to treat Opioid Use
Disorder, it is imperative to highlight certain limitations that may hinder the policy makers in
New Mexico to consider cannabis as a medication to treat opiate use disorder. One limitation is
limited long-term evidence proving the effectiveness of cannabis to treat opiate use disorder as
emphasized by New Mexico’s Department of Health secretary.
Numerous studies focused on the credibility of Cannabis and questions, whether any
positive associations exist between cannabis and treatment for Opioid Use Disorder. One study
published in the American Journal of Psychiatry depicts that cannabis use increases rather than
decreases the risk of developing prescription opioid use disorders (2017). Another recent
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publication, in the February 2018 issue of Addictive Behaviors, concludes that “cannabis use
strengthens, rather than weakens, the relationships between pain and depression and pain and
anxiety” (Barbosa-leiker, Bigand, Cuttler, Gogulski, Oluqoye, Roberts & Wilson, 2018). Most
importantly, cannabis is considered by some, ‘A gateway Drug’ indicating, marijuana use
potentially leads to the use of more hazardous illegal substances. (DeSimone, p.149, 1998).
Despite being labelled as a gateway drug, and recent literature highlighting the benefits derived
along with many states considering cannabis as an alternative option opened doors for more
research on the matter.
Prescription Opioids and Heroin related fatalities have taken its toll on New Mexican
societies. Medical use of Cannabis might prove to be a suitable option for the state to deal with
the current epidemic. Policy maker needs to weigh all the costs and benefits associated with
allowing the use of Medical Cannabis to treat the condition of Opioid Use Disorder. The SWOT
analysis below provides a snapshot of the implications of the initiative, if considered by the
policy makers in the state. It is important to emphasize that further research must be conducted to
study the benefits of allowing medical cannabis for opioid use disorder along with future
consideration of cannabis as part of doctors prescribing practices if proven effective as
alternative to Opioids.
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Table 6
SWOT Analysis: Treating Opioid Use Disorder with Medical Cannabis
Analysis Objectives: The objective of this SWOT analysis is to highlight the implications of
considering Opioid Use Disorder as qualifying condition to enroll in Medical Cannabis
Program. It will provide policy makers with a snapshot of benefits derived from such
intervention, along with certain negative consequences, which will aid policy makers in
making informed decisions.
•
•
•
•
•

•
•
•
•
•

Strengths
Cannabis, as evident is a safe alternative can •
reduce opioid related Over Dose
Cannabis reduces opioid withdrawal
symptoms, leading to improved health, social
functioning and quality of life
•
States with Medical Cannabis laws have
almost 25% lower Opioid related mortality
rate
•
Will lead to decrease in Medicare part D,
prescription drug cost spending
Cannabis use can lead to decline in overdose •
fatalities caused by Prescription opioids and
heroin
•

Weaknesses
Lack of research in the matter of the study
mainly due to federal restrictions, one study
concludes ‘Cannabis use lead to increase
rather than decrease OUD’
Cannabis still considered as schedule I
controlled substance, and some argue that
using cannabis to treat OUD is replacing one
addiction with another
Frequent use carries risk of addiction along
with short-term memory loss
Data suggests states with legal cannabis laws
have high automobile accidents rates
compared to other states
Marijuana is considered by some, as a
gateway drug for other illicit drugs
Threats
Changing political dynamics in New Mexico,
Upcoming legislators might not approve of
the initiative
Illicit drug supply will always be a threat,
consumption of non-medical cannabis cannot
be controlled
Federal government still regards cannabis as
Schedule I controlled substance, state can face
backlash from Federal government
Affordability will be a problem since insurers
do not cover dispensary purchases

Opportunities
Medical cannabis might benefit rural areas of•
NM with lack of treatment centers to treat
OUD
Medical use may reduce illicit marijuana use •
along with black market for other illicit drugs
Dispensary purchases are not covered by
health insurance plans, which will lead to less•
health insurance costs
Medical Cannabis use will reduce stigma and
will encourage more patients to seek OUD •
treatments
Considering OUD as qualifying condition
will open door for future consideration of
adult use legalization, that can be a source of
revenue booster for state
Analysis
New Mexico was ranked 2nd in the country in 2014 for highest overdose deaths, and opioids
were involved in many of those deaths. Several studies highlight the benefits that can be
derived with considering OUD as a qualifying condition to enroll in Medical Cannabis
program and how it eventually leads to reduction in overdose deaths caused by Opioids. Policy
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makers need to weigh all the benefits and costs associated with the implication of such
measure to decide what is best for New Mexicans. Looking at the SWOT analysis, it is
imperative that despite having some disadvantages associated with considering such policy,
containing overdose deaths should be dealt with the highest priority and enough evidence
suggests that Cannabis can play a part in reducing overdose deaths caused by opioids.
Implication of this policy would result in reduction in prescription opioids and heroin
associated abuse and addiction along with reduction in overdose deaths.

In New Mexico, medical cannabis program participation grows by hundreds of patients
every month, and there are currently 58,782 active patients in New Mexico with the highest
number of 29504 patients with Post-traumatic stress disorder and second being patients with
chronic pain conditions” (NMDOH, 2018). Policy makers in the state need to find ways to
accommodate growing number of eligible patients and give significant emphasis on those
seeking Cannabis to treat Opioid Use Disorder. This is a matter of utmost concern and state of
New Mexico need to consider the option within a regulated system to deal with prescription
opioid abuse and heroin crisis leading to large number of overdose deaths.
Effectiveness of Medical cannabis to treat opiate use disorder can provide
opportunity to consider cannabis as part of doctor’s prescribing practices in future. Last
section of the paper highlighted the strengths, weaknesses, opportunities and threats associated
with considering medical cannabis to treat the condition of opiate use disorder. If medical
cannabis use provides positive results, state of New Mexico can adopt measures to ensure
healthcare organizations play their part in addressing the crisis by considering medical cannabis
as a replacement for opiates and by creating an environment where cannabis becomes a part of
physicians prescribing practices. Looking at the current scenario, around 85% of recent medical
school graduates receive no education about cannabis throughout their training, residencies, or
fellowships” (Awad, Bierut, Dufault, Evanoff & Quan, 2007). This is mainly due to federal
restrictions since cannabis is considered as a schedule, I controlled substance.
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In New Mexico currently, Physician referral is required to enroll in Medical Cannabis
Program due to certain chronic conditions like cancer. Though patients self-manage the
frequency, potency and type of cannabis used. Healthcare providers in New Mexico can adopt
measures within the healthcare setting requiring physicians to administer the frequency, potency
and type of cannabis used by the patients who have Opioid Use Disorder.
With the growing concern for abuse of overdose caused by prescription pain relivers,
researchers at the University of Michigan reported that medical cannabis may be an alternative to
more common prescription painkillers for some individuals when national health leaders are
asking the medical community to cut back on prescribing opioids such as Vicodin and
OxyContin (Steinborn, 2018 p.3). State along with healthcare organizations within the state need
to consider alternative measures that would enable hospitals and physicians to dedicate more
efforts in training and studying the benefits of medical cannabis. By prescribing cannabis as an
alternative to opioids, better fitting the needs of different patients with different medical
conditions, physicians can play a part in addressing the problem of opioid use disorder in the
state.
Conclusion
The research of this paper highlights the alarming situation related to prescription
Opioids and Heroin abuse in New Mexico. The purpose of this paper was to get a deeper
understanding of the issue, by providing a historical review of the crisis and by analyzing the
policy interventions of the state government. This research establishes the dire situation of drug
abuse in the state and how it is affecting the local communities. By delving into the impact of
this issue, the paper also highlighted the challenges that the policy makers and people who are
trying to resolve this issue are facing. Based on the research, the recommendations provide a
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framework for some key interventions that the government and policy makers can take to address
the issue.
While this document and the recommendations mentioned can provide a ‘starting point’
to the policy makers, it is important to note that other stakeholders such as big pharmaceutical
companies who benefit from the prescription Opioid medication might be a hurdle in bringing
about change. Another limitation of this research is the challenge of helping those who are
already addicted. New Mexico has scarce resources and budget to deal with the large number of
people with Opioid use disorder. At the end of the day, a very extensive and aggressive strategy
is required by the government to address the ongoing drug abuse crisis and it should make efforts
to bring all stakeholder on board. Only then, the recommendations suggested in this paper and
the existing interventions, efforts and policies will be most effective.
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